Unlocking the Full Potential of Neuroplasticity

Cognesy Therapeutics is building a best-in-class platform technology to discover drugs that induce neuroplasticity for the treatment of neuropsychiatric diseases.

CNS Disorders Worldwide

One in eight people, or 970 million, worldwide currently live with a CNS disorder. While numerous medications are approved for treatment of these disorders, many people living with CNS disease are not adequately treated. Cognesy is focused on unlocking the full potential of neuroplasticity to develop treatments that can work for multiple disorders.

Neuropsychiatric Diseases

280 million

people living with depression

310 million

people living with anxiety

24 million

people living with schizophrenia

55 million

people living with dementia

Acquired Brain Injuries

101 million

annual occurrences of stroke

69 million

annual occurrences of traumatic brain injury

Our Platform

Cognesy is approaching discovery with neuroplasticity-first assays along with novel chemical
libraries and medicinal chemistry.

Culture of rat brain cells stained with antibody to MAP2
GerryShaw, CC BY-SA 3.0, via Wikimedia Commons

Neuroplasticity Screening

  • Neurite outgrowth
  • Synaptogenesis
  • Mechanism of Action
  • Pathway Exploration

Medicinal Chemistry

  • Library Development
  • Structure Activity Relationship
  • Chemical Synthesis

In Vivo Phenotyping

  • Behavioral Models
  • Animal Models/Ex vivo
  • Studies
  • Functional Imaging
  • Safety

Our Team

  • Portrait of Tom Wessel

    Tom Wessel, M.D., Ph.D.

    Chief Executive Officer

  • Portrait of Peter Distefano

    Peter S. DiStefano, Ph.D.

    Co-Founder and Chief Scientific Officer

  • Portrait of Danny Talati

    Danny Talati, Pharm.D., MBA

    SVP, Corporate Strategy

  • Portrait of Joh Byrnes

    John Byrnes, Ph.D.

    Co-Founder and VP, Research

  • Portrait of Gary Bohnert

    Gary Bohnert, Ph.D.

    Co-Founder and Sr. Director, Chemistry